Ondas Holdings (ONDS) News Today — Nov. 8, 2025: Lock‑Up Expiry, Sentrycs Deal Momentum, and Q3 Results Preview

Ondas Holdings (ONDS) News Today — Nov. 8, 2025: Lock‑Up Expiry, Sentrycs Deal Momentum, and Q3 Results Preview

What changed today (Nov. 8) Lock‑up expiration arrives A 60‑day lock‑up covering executive officers, directors and certain significant stockholders—tied to Ondas’ September 9 prospectus supplement—expires today. Market notices published late Friday flagged the lock‑up on warrants, options and RSUs as ending on Nov. 8, 2025. Practically, that can add tradable supply and sometimes amplifies near‑term volatility, though it doesn’t mandate selling. MarketScreener+1 If you want the primary source: Ondas’ September 8‑K includes the form of lock‑up agreement, which sets a “period ending 60 days after the date of the Prospectus.” With the prospectus supplement dated Sept. 9, the 60‑day clock
Qualys (QLYS) Today — Nov 8, 2025: Analyst Upgrade Follows Q3 Beat; Guidance Raised as Stock Hovers Near $150

Qualys (QLYS) Today — Nov 8, 2025: Analyst Upgrade Follows Q3 Beat; Guidance Raised as Stock Hovers Near $150

Qualys, Inc. (NASDAQ: QLYS) is ending the week with fresh analyst attention after posting a stronger‑than‑expected third quarter and raising full‑year guidance earlier this week. As of today, one outlet reports an upgrade to Buy while another highlights lifted EPS forecasts, keeping the cybersecurity name on radar for Google News and Discover readers tracking post‑earnings momentum. The shares are trading around the $150 mark. MarketBeat+1 What’s new today (Nov 8, 2025) Bottom line for Nov 8: The weekend headlines extend a favorable post‑earnings narrative built on raised guidance and improving profitability metrics. Earnings recap: Q3 FY2025 at a glance Qualys
CAVA Stock News Today (Nov 8, 2025): Guidance Cut Fallout, Analyst Target Resets, and What’s Next for CAVA Group (NYSE: CAVA)

CAVA Stock News Today (Nov 8, 2025): Guidance Cut Fallout, Analyst Target Resets, and What’s Next for CAVA Group (NYSE: CAVA)

This week at a glance: why CAVA is in the headlines Analyst moves since the print These updates follow earlier, more bullish initiations earlier in the year, underscoring how quickly sentiment has cooled as traffic moderates. Investopedia+1 By the numbers — Q3 FY2025 (company reported) What to watch next Quick take CAVA’s long runway (415 units vs. a national whitespace) remains intact, but near‑term comps are caught in a consumer downdraft affecting much of fast casual. Management’s choice to protect brand equity—rather than chase discount traffic—means investors will be watching Q4 trends closely to see if loyalty, menu news and
Sling TV adds 159,000 subscribers in Q3 2025 as $4.99 Day/Weekend/Week Passes and new $19.99 “Select” tier drive ~11% sequential growth

Sling TV adds 159,000 subscribers in Q3 2025 as $4.99 Day/Weekend/Week Passes and new $19.99 “Select” tier drive ~11% sequential growth

Why Sling is growing again Sling TV put points on the board in Q3 2025, logging approximately 159,000 net subscriber additions—a turnaround after earlier‑year declines. EchoStar’s Pay‑TV unit (DISH + Sling) closed the quarter with ~7.17 million customers, while the company flagged DISH TV churn at 1.33% (a Q3 low). PR Newswire On a standalone basis, Sling ended Q3 at ~1.995 million subscribers, up about 11% from Q2—momentum that coincided with the start of NFL and NBA seasons and the debut of short‑term passes meant to capture event‑driven viewing. TheDesk.net A quick note on the numbers (and why they’re a
8 November 2025
Ondas Holdings Skyrockets into the U.S. Defense Drone Race – Is ONDS the Next Tech Titan?

Ondas Holdings (ONDS) Jumps as Lock‑Up Expires; Zacks Names ‘Bull of the Day’ and Fresh Fund Buying Sets the Stage Ahead of Nov. 13 Earnings

Date: November 8, 2025 Summary: Ondas Holdings Inc. (NASDAQ: ONDS) capped the week with a sharp Friday rally and a burst of coverage and flow‑of‑funds headlines. A 60‑day lock‑up tied to recent financing expired on Saturday, Nov. 8, while Zacks highlighted the company as its “Bull of the Day” on Friday. Options markets are pricing a double‑digit swing into Thursday’s Q3 report, and at least one wealth manager disclosed a new ONDS stake. Below is everything that moved the story between Nov. 7–8, 2025. Ondas Holdings Inc. What moved ONDS on Friday Shares spiked on heavy volume. ONDS jumped roughly
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer Clinches $10B Takeover of Metsera as Novo Nordisk Bows Out — Full Terms, Timeline, and What It Means (Nov. 8, 2025)

Metsera (NASDAQ: MTSR) and Pfizer struck an amended deal worth up to $10B after Novo Nordisk exited the bidding. Here are the final terms, key dates, and what investors should watch next. Updated: November 8, 2025 Top takeaways What changed on Nov. 7–8 Friday, Nov. 7: Metsera announced an amended merger agreement with Pfizer at $86.25 per share (comprised of $65.60 per share in cash and a contingent value right of up to $20.65). The board unanimously reaffirmed its support for Pfizer’s deal, citing both superior certainty of closing and “unacceptably high legal and regulatory risk” tied to Novo’s competing
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10 Billion Metsera Deal as Novo Nordisk Exits—What It Means for the Obesity Drug Race (Nov. 8, 2025)

Key takeaways What happened (Nov. 7–8) Late Friday, Metsera accepted a sweetened offer from Pfizer: $65.60 per share in cash plus a contingent value right (CVR) of up to $20.65 per share, valuing the biotech at up to $10 billion. On Saturday, Novo Nordisk said it would not increase its bid and exited the race, citing legal and regulatory risks tied to its two‑step proposal. Metsera’s board said Pfizer’s amended agreement carries lower antitrust risk and recommended shareholders approve it at a Nov. 13 meeting. PR Newswire+1 Notably, Pfizer had already received early termination of the HSR waiting period from
Breaking: Eos Energy & MN8 Secure Huge 750 MWh U.S. Battery Storage Deal – Are Stocks Set to Skyrocket?

Eos Energy (EOSE) News Today: Price Target Uplift, Fresh Downgrade, and 70% Warrant Surge — What’s Moving the Stock (Nov 8, 2025)

Updated: November 8, 2025 Key takeaways What’s new today (Nov. 8, 2025) Downgrade lands after the run-up. MarketBeat carried an alert that Wall Street Zen cut EOSE to “Sell” early Saturday, noting the stock’s sharp appreciation and summarizing the existing split in coverage (a mix of Buy/Hold/Sell ratings and an average target near the low teens). While not a bulge-bracket call, the downgrade adds a counterweight to bullish revisions that followed earnings. MarketBeat Fresh transcript color: cash, guidance, and warrants. A newly posted Q3 2025 earnings call transcript highlights management’s stance that execution into Q4 supports the low end of
Qualys (QLYS) News Roundup for Nov. 7–8, 2025: Analyst Upgrade, EPS Estimate Lift, and Stock Holds Near $150 After Q3 Beat

Qualys (QLYS) News Roundup for Nov. 7–8, 2025: Analyst Upgrade, EPS Estimate Lift, and Stock Holds Near $150 After Q3 Beat

Dateline: November 8, 2025 — Cybersecurity vendor Qualys, Inc. (NASDAQ: QLYS) stayed in the headlines heading into the weekend, with fresh analyst reactions following Tuesday’s earnings beat, a state pension fund disclosing a larger stake, and continued chatter around its agentic‑AI roadmap. Below is a concise, Google News–ready digest of everything new about Qualys published November 7–8, 2025. Key Points at a Glance Today — Saturday, Nov. 8, 2025 Analyst upgrade to “Buy.” MarketBeat reports that Wall Street Zen upgraded Qualys shares to Buy today, pointing to the company’s updated FY25 outlook following this week’s results. While this is one
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer Inc. (NYSE: PFE) has secured a definitive agreement to acquire weight‑loss biotech Metsera in a transaction valued at up to $10 billion, ending a high‑stakes bidding war with Novo Nordisk and positioning Pfizer squarely back in the fast‑growing obesity market. Metsera accepted Pfizer’s revised offer late Friday; Novo said today it would not raise its competing bid. Reuters Key takeaways What happened today Pfizer’s final, sweetened bid prevailed after a week of public twists that included legal skirmishes and regulatory warnings. Metsera said the legal and regulatory risks tied to Novo’s proposal—flagged by the FTC—were “unacceptably high,” tipping the
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer sealed a deal to acquire Metsera for up to $10 billion, ending one of 2025’s fiercest pharma bidding wars and reshaping the obesity‑drug race. Below are the facts, context, and what’s next for MTSR shareholders and the GLP‑1 landscape. What happened today Pfizer won the contest for Metsera, agreeing to acquire the clinical‑stage obesity‑drug developer in a transaction valued at up to $10 billion. Metsera’s board cited legal and regulatory certainty in favoring Pfizer’s revised terms, while Novo Nordisk said it will not raise its competing proposal and is exiting the race. The merger is expected to close shortly
EOSE News Today (Nov 8, 2025): Analyst Downgrade Caps Volatile Week After Record Q3; Warrants Jump as New Orders Build

EOSE News Today (Nov 8, 2025): Analyst Downgrade Caps Volatile Week After Record Q3; Warrants Jump as New Orders Build

Eos Energy Enterprises, Inc. (NASDAQ: EOSE) closed out a whipsaw week with fresh weekend headlines: an analyst downgrade, a small fund trimming its position, and continued attention on the company’s Q3 results and growing long‑duration storage pipeline. Below is a concise roundup of what’s new today, plus the key numbers and catalysts investors are watching from this week’s earnings, contracts, and financing updates. Today’s headlines (Nov 8, 2025) Earnings recap: Q3 2025 at a glance Why it matters: The quarter underscores accelerating top‑line traction for zinc‑based, long‑duration storage—but also the ongoing gap to profitability, which is keeping ratings and price

Stock Market Today

Meta stock faces an AI split: ad gains vs a $135 billion bill

Meta stock faces an AI split: ad gains vs a $135 billion bill

7 February 2026
Meta shares dropped 1.3% to $661.46 on Friday after the company projected 2026 capital spending of up to $135 billion, raising investor concerns over cash flow. Meta reported Q4 revenue of $59.89 billion, up 24% year-over-year, with ad impressions rising 18%. Analysts remain divided on whether AI-driven ad gains can offset the steep spending ramp.
IAG share price jumps toward a 52-week peak — what to watch before London reopens

IAG share price jumps toward a 52-week peak — what to watch before London reopens

7 February 2026
IAG shares rose 4.33% to 438.50 pence Friday, near their 52-week high, ahead of full-year results due later this month. The company reported 162,073,135 treasury shares and total voting rights of 4,565,128,012. Brent crude fell 2.2% Thursday to $67.93 a barrel. South Europe Ground Services logged 712,340 operations in 2025 and seeks approval to operate in Portugal.
Go toTop